Montelukast Accord (Montelukast Sodium)

Montelukast, the active ingredient in Montelukast Accord, is a leukotriene receptor antagonist presented as an oral dosage form for oral use. It is used to manage asthma, exercise‑induced bronchoconstriction and allergic rhinitis in adults and children.

GNH USA supplies Montelukast Accord as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The company follows EU GMP standards, provides full regulatory dossiers and offers reliable logistics for global distribution.

Montelukast acts on the leukotriene pathway to control airway inflammation and bronchoconstriction.

Asthma: reduces frequency of wheezing episodes and improves lung function. Exercise‑induced bronchoconstriction: prevents narrowing of airways during physical activity. Allergic rhinitis: alleviates nasal congestion, sneezing and itching.

Montelukast may cause a range of adverse reactions, from mild to severe.

Common Side Effects: - Headache - Abdominal pain - Cough - Nausea - Dizziness

Serious or Rare Side Effects: - Angioedema - Stevens‑Johnson syndrome - Hepatic injury - Neuropsychiatric events such as agitation or suicidal thoughts

When prescribing Montelukast, consider specific safety aspects. - Pregnancy: Category B; use only if benefit outweighs risk. - Lactation: Small amounts excreted in breast milk; evaluate infant risk. - Pediatric use: Safety established in children ≥6 months; follow prescriber guidance. - Hepatic impairment: Use with caution; monitor liver enzymes. - Hypersensitivity: Discontinue if allergic reaction occurs. - Store below 25°C: keep in original packaging, protect from moisture.

Montelukast can interact with several medicines, requiring attention to avoid reduced efficacy or increased toxicity.

Major Interactions (Avoid): - Rifampin, phenobarbital, carbamazepine: strong CYP3A4 inducers that lower montelukast exposure. - St. John’s wort: herbal CYP3A4 inducer may reduce effectiveness. - Concurrent use with other leukotriene pathway inhibitors (e.g., zafirlukast) may increase adverse‑effect risk.

Moderate Interactions (Monitor Closely): - Warfarin: montelukast may enhance anticoagulant effect; monitor INR. - Theophylline: possible increase in plasma levels; observe for toxicity. - Oral contraceptives: may slightly raise hormone levels; monitor for menstrual changes.